stonks4u
Sign up free
IMDX logo

IMDX Insight Molecular Diagnostics Inc.

NASDAQ Capital Market · Medical - Diagnostics & Research · Healthcare

$4.32
+0.61 (+16.44%)

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcin…

Market Cap: $139.49Mimdxinc.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 11Aug 11

Quote

Day Range
$3.76 – $4.36
52-Week Range
$2.33 – $8.51
Volume
$331.4K
Market Cap
$139.49M
50-Day Avg
$5.09
200-Day Avg
$5.43
Prev Close
$3.71
Open
$3.76

Valuation & Ratios

P/E Ratio
-4.55
EPS
$-1.65
P/B Ratio
-7.26
P/S Ratio
56.37
Debt/Equity
-0.11
Current Ratio
1.27
Dividend Yield
+0.0%
Gross Margin
+4.7%

Returns & Efficiency

Return on Equity
+159.6%
Return on Assets
-195.0%
FCF Yield
-11.1%
EV/EBITDA
-4.60

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$4.05M$-50.22M$-1.65
2024$1.88M$-60.66M$-4.66
2023$1.50M$-27.78M$-3.75
2022$958.0K$-72.90M$-20.00
2021$2.20M$-64.10M$-14.40

Social Signal Score

70
5d
70
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.23 per share

2of 7 quarters beat consensus

Typical surprise -13.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-0.31 vs $-0.25miss
  • Wed, May 13$-0.12 vs $-0.26beat
  • Thu, Mar 26$-0.27 vs $-0.24miss
  • Mon, Nov 10$-0.34 vs $-0.24miss
  • Mon, Aug 11$-0.30 vs $-0.23miss
  • Mon, May 12$-0.26 vs $-0.24miss

Estimates and results for IMDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

IMDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsseekingalpha.com·4d ago·Positive

    Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript

    View source ↗